Biopharmaceutical drug pricing and market access contracting has become more complicated and interrelated than ever.  The profitability of both pricing decisions and contracting decisions are now firmly linked and a quickly evolving legislative and regulatory shift in the area of state price transparency reporting is further elevating the compliance implications of adjustments in price.  Finally, the march from volume-based to value-based commercial models demands the linkage of outcomes and real world data to be linked into this broader solution footprint.

Learn about a more integrated and intuitive approach to linking pricing, contracting, and value-based decisions to create organizational agility and an ability to scale in this quickly changing complex landscape.  Join us to discuss how this inter-connected approach can have a radical impact on the profitability of life sciences organizations as well as align incentives across the health care ecosystems.

Featured Speaker

David Carlson

Market Access & Pricing Offering Leader and Managing Director
Deloitte Consulting LLP 

David leads ConvergeHEALTH’s Market Access and Pricing offering for ConvergeHEALTH by Deloitte and is a Managing Director with Deloitte Consulting LLP. He is an experienced management consultant and entrepreneur with a demonstrated history of growing transformational organizations from early stages to maturity and exit. David was co-owner and COO of a predictive analytics software and services company serving the life sciences industry, which was purchased by a tier I Silicon Valley private equity firm. He has also served a number of data and analytics startups serving life sciences. David’s consulting work has focused primarily on the strategic use of analytics to solve complex commercial needs for both large and emerging pharmaceutical and biotechnology clients, as well as on market access. He has led initiatives in the areas of pricing and reimbursement, value-based strategies, managed markets analytics, product launch scenario planning, and fact-based negotiation. David has had articles published in industry publications such as Pharmaceutical Executive and contributed to the book Debates on US Health Care (2012, Sage Publishing).

Paul Silver

Risk & Financial Advisory Life Sciences Regulatory and Compliance Leader and Principal
Deloitte & Touche LLP

Paul is the Risk & Financial Advisory Life Sciences Regulatory and Compliance leader and Principal with Deloitte & Touche LLP. He has 30 years of experience in the pharmaceutical, medical device, and consumer products industry specializing in compliance and regulatory matters. Paul regularly works with in-house legal counsel, corporate compliance officers, senior operations professionals, and outside legal counsel that support these professionals. Paul provides industry insight on various government health care investigations related to the sales and marketing of drugs and devices and has provided expert testimony on behalf of pharmaceutical companies in litigation matters involving sales and marketing practices.

Clay Willis

Risk & Financial Advisory Senior Manager
Deloitte & Touche LLP

Clay is a Risk & Financial Advisory senior manager for Deloitte & Touche LLP, specializing in Regulatory and Legal Support within the Life Sciences and Health Care industry. Clay has over a 14 years of consulting experience in the pharmaceutical, medical device, and health care industry. He has experience in providing operational, financial, and compliance support to small, mid-size, and large pharmaceutical and medical device manufacturers. In addition, he has presented various points of view at industry conferences, through webinars and written publications. He has expertise in: Government Program Compliance, Commercial Contracting, System and Managed Service Implementations, 340B Program Integrity, State Price Transparency, Value Based Contracting, and other various Government Program compliance areas.

Date:  Wednesday, June 30, 2021
Time:  1pm ET / 10am PT
Duration:  1 Hour

Register now for this webinar